Brolucizumab Solution for Injection — Anti-VEGF Therapy for Wet Age-Related Macular Degeneration
Pagenax® (Brolucizumab) — Targeted Anti-VEGF Therapy for Wet AMD
A Sourcing Guide for Hospitals, Ophthalmology Clinics, and Pharmacies
Pagenax® (Brolucizumab) is a humanised single-chain antibody fragment indicated, according to the manufacturer’s approved prescribing information, for the treatment of neovascular (wet) age-related macular degeneration (AMD). As with all ophthalmology biologics, the decision to prescribe Pagenax, including administration and follow-up scheduling, rests entirely with the treating ophthalmologist, in accordance with the approved label. This page provides sourcing and procurement information for hospitals, clinics, and pharmacies, not clinical or treatment guidance.
As both a trusted medicine distributor in Delhi and a licensed pharmaceutical distributor in Delhi, A.K. Pharma supplies genuine Pagenax (Brolucizumab) to hospitals, ophthalmology clinics, and pharmacies across India, manufactured by Novartis India Ltd.
Pagenax contains Brolucizumab, a humanised single-chain antibody fragment (scFv) that selectively targets vascular endothelial growth factor-A (VEGF-A), a protein implicated in the abnormal blood vessel growth characteristic of wet AMD.
VEGF and the Pathophysiology of Wet AMD:
According to published ophthalmology literature, wet AMD is characterised by choroidal neovascularisation — the abnormal growth of new, fragile blood vessels beneath the retina, driven substantially by elevated VEGF signalling. These new vessels are prone to leaking fluid and blood, causing macular oedema, retinal distortion, and progressive vision loss if left untreated. Unlike dry AMD, which progresses more slowly through retinal cell degeneration, wet AMD can cause more rapid and severe vision loss due to this vascular leakage and structural disruption.
Brolucizumab’s Mechanism: By binding to and inhibiting VEGF-A, Brolucizumab suppresses the signalling that drives abnormal choroidal neovascularisation and vascular permeability, according to the manufacturer’s prescribing information. Its smaller molecular size compared to earlier anti-VEGF agents was designed to allow higher molar concentrations of active drug to be delivered per injection, according to the developer’s published pharmacology data, which has been studied in relation to treatment durability.
Full prescribing information is available at the FDA label for Brolucizumab, with additional background on wet AMD pathophysiology available via the National Eye Institute.
HAWK and HARRIER Trials (Brolucizumab vs Aflibercept in Wet AMD)
Published in Ophthalmology (2020), the pivotal HAWK and HARRIER Phase 3 trials compared Brolucizumab against Aflibercept, an established anti-VEGF therapy, in patients with wet AMD. Key findings included non-inferior visual acuity outcomes for Brolucizumab compared to Aflibercept, along with a higher proportion of Brolucizumab-treated patients maintaining a quarterly (every 12-week) dosing interval after the initial loading phase, compared to the fixed 8-week interval used with Aflibercept in these trials. Anatomical outcomes, including reduction in retinal fluid, also favoured Brolucizumab in these studies.
For broader clinical guidance on anti-VEGF therapy in retinal disease, the American Academy of Ophthalmology publishes ongoing treatment pattern guidance for retina specialists.
Pagenax is available as:
| Presentation | Strength | Administration |
|---|---|---|
| Pagenax Solution for Injection | Per manufacturer specification | Intravitreal injection |
Dosing and injection interval are determined by the prescribing ophthalmologist based on individual disease activity assessment, in accordance with the approved label.
Neovascular (Wet) Age-Related Macular Degeneration:
For detailed indication information refer to MedlinePlus Macular Degeneration.
Extended Dosing Interval Potential
The HAWK and HARRIER trials demonstrated that a meaningful proportion of Brolucizumab-treated patients were able to maintain a 12-week dosing interval after the loading phase, which may be relevant for patients and treating ophthalmologists considering treatment burden alongside efficacy.
Demonstrated Anatomical Improvement
Trial data showed favourable outcomes in retinal fluid reduction, a key anatomical marker of disease activity monitored by ophthalmologists in wet AMD management.
Established Efficacy Compared to Existing Anti-VEGF Therapy
HAWK and HARRIER demonstrated non-inferior visual acuity outcomes compared to Aflibercept, providing ophthalmologists with a comparative evidence base when considering treatment options.
Administration of Pagenax is performed exclusively by a qualified ophthalmologist via intravitreal injection under sterile conditions. General information from the manufacturer’s prescribing information includes:
Monitoring (per manufacturer prescribing information):
Full administration guidelines are available in the manufacturer’s official prescribing information and should always be followed exactly as directed by the treating ophthalmologist.
Pagenax is administered by ophthalmologists and retina specialists for:
Pagenax is administered exclusively in a clinical setting by qualified ophthalmology specialists. A.K. Pharma supplies Pagenax to hospitals and ophthalmology clinics across Delhi and India.
Common side effects reported in clinical trials include conjunctival haemorrhage, vitreous floaters, and eye pain associated with the injection procedure.
Serious side effects include:
Intraocular Inflammation, Including Retinal Vasculitis and Retinal Vascular Occlusion: These events have been reported with Brolucizumab and are addressed in the approved prescribing information; prompt evaluation of new visual symptoms following injection is recommended per the approved label.
Endophthalmitis: As with other intravitreal injections, a risk of intraocular infection exists; sterile injection technique and prompt evaluation of post-injection symptoms such as pain, redness, or vision changes is recommended.
Retinal Detachment: A rare but serious risk associated with intravitreal injection procedures generally.
Increased Intraocular Pressure: Transient or sustained elevation in intraocular pressure has been reported following injection.
Full side effect information is available at FDA Brolucizumab Safety Information.
As a responsible medicine distributor in Delhi, A.K. Pharma stores all ophthalmology biologics including Pagenax under manufacturer-recommended cold chain conditions ensuring product integrity for every supply.
Pagenax (Brolucizumab) is manufactured by Novartis India Ltd. Brolucizumab received regulatory approval for the treatment of neovascular (wet) age-related macular degeneration. A.K. Pharma supplies only genuine Pagenax sourced from authorised distributors. Learn more about Novartis’s ophthalmology and broader portfolio directly from the manufacturer.
Q. What is Pagenax used for?
Pagenax (Brolucizumab) is used to treat neovascular (wet) age-related macular degeneration, administered by an ophthalmologist as an intravitreal injection.
Q. What is the generic name of Pagenax?
The generic name of Pagenax is Brolucizumab, an anti-VEGF therapy manufactured by Novartis India.
Q. How often is Pagenax administered?
Pagenax typically begins with a monthly loading phase, followed by an individualised maintenance schedule, which may extend to every 12 weeks for some patients, determined by the treating ophthalmologist based on disease activity.
Q. Can Pagenax be self-administered?
No. Pagenax is administered exclusively by a qualified ophthalmologist via intravitreal injection under sterile clinical conditions; it is not a self-administered medicine.
Q. Is Pagenax available in India?
Pagenax can be supplied to hospitals and ophthalmology clinics across India through licensed pharmaceutical distributors. Contact A.K. Pharma — medicine distributor in Delhi and pharmaceutical distributor in Delhi — for availability and pricing.
Q. What is the price of Pagenax in India?
Pagenax price in India varies by order quantity. Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827 for current pricing and bulk supply rates.
Q. How to order Pagenax from A.K. Pharma?
You can request a quote directly from this page, call us at 011 4172 6999, or WhatsApp us at +91 9810034827 with your requirements and we will respond promptly.
Q. Does A.K. Pharma supply Pagenax in bulk?
Yes. A.K. Pharma supplies Pagenax in bulk to hospitals and ophthalmology clinics across Delhi and India.
📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052
📞 011 4172 6999
📱 WhatsApp: +91 9810034827
🌐 akpharma.in
Disclaimer: This page is intended for informational and sourcing/procurement purposes only and does not constitute medical or clinical advice. All treatment decisions should be made by a qualified ophthalmologist in accordance with the approved prescribing information. A.K. Pharma is a licensed medicine distributor and does not provide clinical guidance.
